Enanta Pharmaceuticals Inc (NASDAQ:ENTA) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,230,300 shares, an increase of 15.7% from the July 31st total of 1,928,200 shares. Based on an average trading volume of 192,500 shares, the days-to-cover ratio is currently 11.6 days. Currently, 14.1% of the shares of the stock are sold short.

NASDAQ ENTA traded down $1.43 during trading on Friday, hitting $67.97. 135,775 shares of the company’s stock traded hands, compared to its average volume of 178,090. The stock has a fifty day moving average of $71.72 and a two-hundred day moving average of $86.42. Enanta Pharmaceuticals has a 12-month low of $63.37 and a 12-month high of $106.80. The firm has a market cap of $1.38 billion, a P/E ratio of 19.53 and a beta of 0.97.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.27. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. The business had revenue of $44.40 million during the quarter, compared to analyst estimates of $46.98 million. During the same period in the prior year, the business posted $0.97 earnings per share. The company’s revenue was down 22.5% on a year-over-year basis. On average, sell-side analysts anticipate that Enanta Pharmaceuticals will post 2.47 earnings per share for the current year.

A number of research firms recently commented on ENTA. BidaskClub cut Enanta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Wolfe Research began coverage on Enanta Pharmaceuticals in a research note on Friday, May 24th. They issued an “outperform” rating and a $117.00 target price on the stock. Finally, Zacks Investment Research cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $104.75.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at about $34,000. South Dakota Investment Council purchased a new stake in Enanta Pharmaceuticals during the first quarter valued at about $76,000. Bank of Montreal Can boosted its position in Enanta Pharmaceuticals by 198.3% during the second quarter. Bank of Montreal Can now owns 2,300 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 1,529 shares during the period. Jane Street Group LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at about $208,000. Finally, GAM Holding AG purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at about $215,000. Institutional investors and hedge funds own 88.79% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Read More: Cash Asset Ratio

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.